WO2000009666A3 - Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof - Google Patents

Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof Download PDF

Info

Publication number
WO2000009666A3
WO2000009666A3 PCT/US1999/018099 US9918099W WO0009666A3 WO 2000009666 A3 WO2000009666 A3 WO 2000009666A3 US 9918099 W US9918099 W US 9918099W WO 0009666 A3 WO0009666 A3 WO 0009666A3
Authority
WO
WIPO (PCT)
Prior art keywords
producing cells
insulin producing
exendin
glp
insulin
Prior art date
Application number
PCT/US1999/018099
Other languages
French (fr)
Other versions
WO2000009666A9 (en
WO2000009666A2 (en
Inventor
Josephine Egan
Riccardo Perfetti
Antonino Passaniti
Nigel Greig
Harold Holloway
Original Assignee
Us Gov Health & Human Serv
Josephine Egan
Riccardo Perfetti
Antonino Passaniti
Nigel Greig
Harold Holloway
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU55524/99A priority Critical patent/AU776514B2/en
Priority to EP99942066A priority patent/EP1105460B1/en
Priority to DK99942066.4T priority patent/DK1105460T3/en
Priority to AT99942066T priority patent/ATE445006T1/en
Priority to US09/762,538 priority patent/US7056734B1/en
Priority to CA002339326A priority patent/CA2339326A1/en
Application filed by Us Gov Health & Human Serv, Josephine Egan, Riccardo Perfetti, Antonino Passaniti, Nigel Greig, Harold Holloway filed Critical Us Gov Health & Human Serv
Priority to JP2000565103A priority patent/JP4624558B2/en
Priority to DE69941510T priority patent/DE69941510D1/en
Publication of WO2000009666A2 publication Critical patent/WO2000009666A2/en
Publication of WO2000009666A9 publication Critical patent/WO2000009666A9/en
Publication of WO2000009666A3 publication Critical patent/WO2000009666A3/en
Priority to US11/400,715 priority patent/US20070041951A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin

Abstract

The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragmets thereof. The present invention also relates to methods of differentiating non-insulin producing cells into insulin producing cells and of enriching a population of cells for insulin-producing cells. The present invention also relates to methods of treating diabetes.
PCT/US1999/018099 1998-08-10 1999-08-10 Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof WO2000009666A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP99942066A EP1105460B1 (en) 1998-08-10 1999-08-10 Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
DK99942066.4T DK1105460T3 (en) 1998-08-10 1999-08-10 Differentiation of non-insulin producing cells into insulin producing cells with GLP-1 or Exendin-4 and uses thereof
AT99942066T ATE445006T1 (en) 1998-08-10 1999-08-10 DIFFERENTIATION OF NON-INSULIN INTO INSULIN-PRODUCING CELLS BY GLP-1 AND EXENDIN-4 AND THEIR USE
US09/762,538 US7056734B1 (en) 1998-08-10 1999-08-10 Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
CA002339326A CA2339326A1 (en) 1998-08-10 1999-08-10 Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
AU55524/99A AU776514B2 (en) 1998-08-10 1999-08-10 Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
JP2000565103A JP4624558B2 (en) 1998-08-10 1999-08-10 Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4 and use thereof
DE69941510T DE69941510D1 (en) 1998-08-10 1999-08-10 DIFFERENTIATION OF NON-INSULIN IN INSULIN-PRODUCING CELLS BY GLP-1 AND EXENDIN-4 AND THEIR USE
US11/400,715 US20070041951A1 (en) 1998-08-10 2006-04-07 Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9591798P 1998-08-10 1998-08-10
US60/095,917 1998-08-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/400,715 Continuation US20070041951A1 (en) 1998-08-10 2006-04-07 Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof

Publications (3)

Publication Number Publication Date
WO2000009666A2 WO2000009666A2 (en) 2000-02-24
WO2000009666A9 WO2000009666A9 (en) 2000-07-13
WO2000009666A3 true WO2000009666A3 (en) 2000-11-23

Family

ID=22254191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/018099 WO2000009666A2 (en) 1998-08-10 1999-08-10 Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof

Country Status (10)

Country Link
US (2) US7056734B1 (en)
EP (2) EP2028269B1 (en)
JP (4) JP4624558B2 (en)
AT (1) ATE445006T1 (en)
AU (1) AU776514B2 (en)
CA (1) CA2339326A1 (en)
DE (1) DE69941510D1 (en)
DK (1) DK1105460T3 (en)
ES (2) ES2553108T3 (en)
WO (1) WO2000009666A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US6703017B1 (en) 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US6699973B1 (en) * 1998-11-19 2004-03-02 Elan Corporation, Plc Antibodies to peptides that target GIT receptors and related methods
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US6967019B2 (en) * 1999-04-06 2005-11-22 The Regents Of The University Of California Production of pancreatic islet cells and delivery of insulin
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US20030082155A1 (en) * 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US6448045B1 (en) 2000-03-10 2002-09-10 The Regents Of The University Of California Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
EP1346722B1 (en) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
EP2275117B1 (en) 2001-07-31 2016-10-26 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
US6642003B2 (en) 2001-08-02 2003-11-04 Cedars-Sinai Medical Center Human glucose-dependent insulin-secreting cell line
US6911324B2 (en) 2001-10-18 2005-06-28 The Regents Of The University Of California Induction of beta cell differentiation in human cells
JP2005533480A (en) * 2001-11-09 2005-11-10 アーテセル・サイエンシズ・インコーポレーテツド Pancreatic endocrine differentiation of adipose tissue-derived stromal cells and use thereof
EP2277888A3 (en) 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
DE60335608D1 (en) * 2002-02-27 2011-02-17 Pharmain Corp COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
AU2003228255A1 (en) * 2002-05-28 2003-12-19 Becton, Dickinson And Company Pancreatic acinar cells into insulin-producing cells
EP1688148A1 (en) * 2002-12-03 2006-08-09 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
EP1569682A2 (en) * 2002-12-03 2005-09-07 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
DE602004031927D1 (en) 2003-02-04 2011-05-05 Novo Nordisk As INJECTION DEVICE WITH ROTATABLE DOSE ADJUSTMENT DEVICE
EP1636348B1 (en) * 2003-06-20 2009-07-29 Vrije Universiteit Brussel VUB Method of generating islet beta-cells from exocrine pancreatic cells
EP1641913B1 (en) 2003-06-27 2016-01-06 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
EP2444397A1 (en) 2004-01-06 2012-04-25 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
ATE550041T1 (en) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag TRANSGLUTAMINASE-MEDIATED CONJUGATION OF PEPTIDES
EP1767618A4 (en) * 2004-06-03 2008-07-30 Univ Kyoto Induction of insulin secreting cell
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
BRPI0612996A2 (en) 2005-07-14 2010-12-14 Novo Nordisk As urea glucokinase activators
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PL1971681T3 (en) 2005-12-16 2018-01-31 Depuy Synthes Products Inc Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
KR101872061B1 (en) 2005-12-19 2018-06-27 파마인 코포레이션 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
EP2241327A1 (en) 2006-03-15 2010-10-20 Novo Nordisk A/S Mixtures of Amylin and Insulin
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2099777B1 (en) 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
RU2413528C2 (en) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Exenatide and dalargin drug for treating diabetes, adminisration and therapy
CN101743252A (en) 2007-07-16 2010-06-16 诺沃-诺迪斯克有限公司 protease stabilized, pegylated insulin analogues
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US20110046071A1 (en) * 2008-03-05 2011-02-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer
PL2910570T3 (en) 2008-03-18 2017-06-30 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
US10557116B2 (en) 2008-12-19 2020-02-11 DePuy Synthes Products, Inc. Treatment of lung and pulmonary diseases and disorders
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
AU2010229651B2 (en) 2009-03-26 2014-05-08 Advanced Technologies And Regenerative Medicine, Llc Human umbilical cord tissue cells as therapy for Alzheimer' s disease
CN101991580B (en) * 2009-08-28 2013-03-20 杏辉天力（杭州）药业有限公司 Application of lanostane and poria cocos extracts in diabetes treatment
EP2504019A2 (en) 2009-11-25 2012-10-03 ArisGen SA Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
JP5969461B2 (en) 2010-04-27 2016-08-17 ジーランド ファーマ アクティーゼルスカブ Peptide complex of GLP-1 receptor agonist and gastrin and use thereof
JP5866106B2 (en) 2010-05-12 2016-02-17 コロンビア ユニヴァーシティ Method for producing enteroendocrine cells that produce and secrete insulin
TW201326194A (en) 2011-11-03 2013-07-01 Zealand Pharma As GLP-1 gastrin receptor agonist peptide conjugates
SG11201403465PA (en) 2011-12-23 2014-10-30 Atrm Llc Detection of human umbilical cord tissue-derived cells
ES2620111T3 (en) 2012-07-23 2017-06-27 Zealand Pharma A/S Glucagon analogues
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
PL2934567T3 (en) 2012-12-21 2018-10-31 Sanofi Exendin-4 derivatives as dual glp1/gip- or trigonal glp1/gip/glucagon agonists
DK3057984T3 (en) 2013-10-17 2018-10-08 Zealand Pharma As ACYLED GLUCAGON ANALOGS
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EA035688B1 (en) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Glucagon-glp-1-gip triple agonist compounds
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/GIP receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
CN106232623A (en) * 2014-04-22 2016-12-14 Txp制药股份有限公司 There is the peptide analogues of branched-amino acid probe
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3160503B1 (en) 2014-06-26 2021-02-17 The Trustees of Columbia University in the City of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
RU2573933C1 (en) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Peptide for medical treatment of pancreatic diabetes of 2nd type and its complications
BR112017008659A2 (en) 2014-10-29 2018-01-30 Zealand Pharma As ? gip agonist methods and compounds?
PL3283507T3 (en) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylated glucagon analogue
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
EP3551651B1 (en) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
CN109679964A (en) * 2019-01-12 2019-04-26 青岛华义宏博生物科技有限公司 A kind of Recombinant Lactococcus lactis for expressing human insulin gene
US20220315632A1 (en) 2019-03-15 2022-10-06 Diet4Life Aps Combination of dietary peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1995031214A1 (en) * 1994-05-12 1995-11-23 London Health Association Treatment of diabetes
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
AU4114493A (en) * 1992-04-24 1993-11-29 Polymer Technology Group, Inc., The Method of culturing viable cells and method of regulating the level of a compound in a body fluid
SK155694A3 (en) 1992-06-15 1995-05-10 Pfizer Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
EP0966297B2 (en) * 1996-08-08 2013-02-27 Amylin Pharmaceuticals, Inc. Regulation of gastrointestinal motility
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1995031214A1 (en) * 1994-05-12 1995-11-23 London Health Association Treatment of diabetes
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GEFEL ET AL: "GLUCAGON-LIKE PEPTIDE-I ANALOGS: EFFECTS ON INSULIN SECRETION AND ADENOSINE 3',5'-MONOPHOSPHATE FORMATION", ENDOCRINOLOGY, vol. 126, no. 4, 1990, pages 2164 - 2168, XP000574862, ISSN: 0013-7227 *
MASHIMA ET AL: "FORMATION OF INSULIN-PRODUCING CELLS FROM PANCREATIC ACINAR AR42J CELLS BY HEPATOCYTE GROWTH FACTOR", ENDOCRINOLOGY, vol. 137, no. 9, 1996, pages 3969 - 3976, XP000670297, ISSN: 0013-7227 *
THORENS B ET AL: "CLONING AND FUNCTIONAL EXPRESSION OF THE HUMAN ISLET GLP-1 RECEPTORÖDEMONSTRATION THAT EXENDIN-4 IS AN AGONIST AND EXENDIN-(9-39) AN ANTAGONIST OF THE RECEPTOR", DIABETES, vol. 42, no. 11, 1 November 1993 (1993-11-01), pages 1678 - 1682, XP000571435, ISSN: 0012-1797 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors

Also Published As

Publication number Publication date
JP4755133B2 (en) 2011-08-24
CA2339326A1 (en) 2000-02-24
AU776514B2 (en) 2004-09-09
DE69941510D1 (en) 2009-11-19
EP2028269A1 (en) 2009-02-25
EP1105460B1 (en) 2009-10-07
ATE445006T1 (en) 2009-10-15
WO2000009666A9 (en) 2000-07-13
JP2002522068A (en) 2002-07-23
JP2007209348A (en) 2007-08-23
US20070041951A1 (en) 2007-02-22
ES2335066T3 (en) 2010-03-18
WO2000009666A2 (en) 2000-02-24
DK1105460T3 (en) 2010-02-08
JP2009291206A (en) 2009-12-17
ES2553108T3 (en) 2015-12-04
AU5552499A (en) 2000-03-06
JP4624558B2 (en) 2011-02-02
EP1105460A2 (en) 2001-06-13
JP2011177181A (en) 2011-09-15
US7056734B1 (en) 2006-06-06
EP2028269B1 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
WO2000009666A3 (en) Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
YU59392A (en) A-B-C PROINSULIN, OBTAINING PROCESS AND INTERMEDIARIES IN INSULIN PRODUCTION
DK2210947T3 (en) Process for the production of secreted proteins
ATE168605T1 (en) PRODUCTION OF UNIFORM SIZE QUANTUM ISLAND POWDER
AU5027299A (en) Use of glp-1 and analogues for preventing type ii diabetes
WO2003014318A3 (en) Methods for treating diabetes and other blood sugar disorders
MY119174A (en) Process for the production of chemically prestressed glass, and the use thereof
DE59915077D1 (en) Process for the fermentative production of D-pantothenic acid by amplification of the panD gene in microorganisms
WO2002044362A1 (en) Method of screening remedy for diabetes
WO2001003680A3 (en) Compounds for inhibiting diseases and preparing cells for transplantation
ATE403008T1 (en) METHOD FOR PRODUCING L-AMINO ACIDS USING STRAINS FROM THE ENTEROBACTERIACEA FAMILY WHICH CONTAIN AN ATTENUATE DGSA GENE
DE502004000547D1 (en) Process for the fermentative production of L-methionine
EP0158892A3 (en) 59 valine insulin-like growth factor i and process for production thereof
HU896613D0 (en) Process for the preparation of tgf-betal/beta2 chimer
AU2099301A (en) Method for obtaining proteins having improved functional characteristics
DE69803805D1 (en) NEW MATERIAL AND METHOD FOR THE PRODUCTION THEREOF
DE59807382D1 (en) Mutants of formate dehydrogenase from Candida biodinii, gene sequences encoding them and use of these formate dehydrogenases
WO2003080666A3 (en) An adipocyte insulin and a method of treating diabetes
WO2010094587A1 (en) Microbial siderophore synthesis
SK97195A3 (en) Dnk - sequences coding the new biosynthetic precursors of insulin and method of insuline preparation
EP0850970A3 (en) Process for preparing the polycarbonate of 2,2,4,4-tetramethyl-1,3-cyclobutanediol
WO1997035993A3 (en) PSA positive regulating (PSAR) sequences and uses thereof
EP1295937A2 (en) Candida boidinii formic hydrogenase mutants
EP0828004A3 (en) Protein disulfide isomerase gene derived from strain of methylotrophic yeast
CA2214805A1 (en) Process for biological control of calamagrostis canadensis using a low temperature basidiomycete

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/30-30/30, DRAWINGS, REPLACED BY NEW PAGES 1/26-26/26; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2339326

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2339326

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999942066

Country of ref document: EP

Ref document number: 55524/99

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999942066

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09762538

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 55524/99

Country of ref document: AU